PMD Healthcare Inc.
Personal spirometer helps patients with obstructive lung diseases
This article was originally published in Start Up
Executive Summary
The current tool by which patients with lungs diseases (like asthma and COPD) measure their own lung function at home, the peak expiratory flow meter, is not sufficiently informative enough to guide decision-making. PMD Healthcare aims to help respiratory patients care for their disease better. The company has developed a spirometer for home use, Spiro PD, that works on the same principles as the well-accepted office-based and hospital spirometers, but is easy to use and affordable.
You may also be interested in...
COPD Post-Market Requirements: Cardiovascular Safety Could Evolve to Comparative Trials
Forest's aclidinium breezed through an advisory committee review with three strong votes in favor of approval. The FDA panel, however, also included an interesting call for more head-to-head trials in COPD from the outgoing panel chair. That may impact Forest's Phase IV work--but more importantly it may be a sign of the future expectations for other sponsors in the active COPD development area.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.